Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1987 1
1990 3
1991 4
1992 1
1993 1
1994 2
1995 2
1997 2
1999 1
2000 1
2002 1
2006 1
2008 1
2009 1
2010 5
2011 5
2012 8
2013 5
2014 5
2015 6
2016 9
2017 4
2018 4
2019 2
2020 1
2021 3
2022 2
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
Uhrenholt L, Christensen R, Dreyer L, Hauge EM, Schlemmer A, Loft AG, Rasch M, Horn HC, Gade KH, Østgård RD, Taylor PC, Duch K, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Scand J Rheumatol. 2023 Sep;52(5):481-492. doi: 10.1080/03009742.2023.2164979. Epub 2023 Feb 6. Scand J Rheumatol. 2023. PMID: 36745114 Clinical Trial.
Auditing chronic disease care: Does it make a difference?
Essel V, van Vuuren U, De Sa A, Govender S, Murie K, Schlemmer A, Gunst C, Namane M, Boulle A, de Vries E. Essel V, et al. Among authors: schlemmer a. Afr J Prim Health Care Fam Med. 2015 Jun 26;7(1):753. doi: 10.4102/phcfm.v7i1.753. Afr J Prim Health Care Fam Med. 2015. PMID: 26245615 Free PMC article.
Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
Uhrenholt L, Christensen R, Dinesen WKH, Liboriussen CH, Andersen SS, Dreyer L, Schlemmer A, Hauge EM, Skrubbeltrang C, Taylor PC, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Rheumatology (Oxford). 2022 Aug 3;61(8):3107-3122. doi: 10.1093/rheumatology/keab902. Rheumatology (Oxford). 2022. PMID: 34864896
Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study.
Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge EM, Krogh NS, Abildtoft MK, Taylor PC, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. Scand J Rheumatol. 2022 Jan;51(1):25-33. doi: 10.1080/03009742.2021.1907925. Epub 2021 Jun 21. Scand J Rheumatol. 2022. PMID: 34151710 Clinical Trial.
Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial.
Holm Nielsen S, Sardar S, Siebuhr AS, Schlemmer A, Schmidt EB, Bay-Jensen AC, Karsdal MA, Christensen JH, Kristensen S. Holm Nielsen S, et al. Among authors: schlemmer a. Rheumatol Int. 2021 Jun;41(6):1065-1077. doi: 10.1007/s00296-021-04861-z. Epub 2021 Apr 22. Rheumatol Int. 2021. PMID: 33885930 Free PMC article. Clinical Trial.
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
Uhrenholt L, Schlemmer A, Hauge EM, Christensen R, Dreyer L, Suarez-Almazor ME, Kristensen S. Uhrenholt L, et al. Among authors: schlemmer a. BMJ Open. 2019 Jul 9;9(7):e028517. doi: 10.1136/bmjopen-2018-028517. BMJ Open. 2019. PMID: 31292181 Free PMC article.
69 results